Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 3:00 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Maraviroc 300 mg Clear all
Terminated Phase 3 Interventional Results available

Comparative Trial Of Maraviroc Versus Emtricitabine/Tenofovir Both With Darunavir/Ritonavir In Antiretroviral-Naive Patients Infected With CCR5 Tropic HIV 1

NCT01345630
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc, Emtricitabine/tenofovir, darunavir/ritonavir 800/100 mg, placebo for emtricitabine/tenofovir, placebo for maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
84
States / cities
Birmingham, Alabama • Hobson City, Alabama • Hayward, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Oct 17, 2026, 3:00 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

NCT00042289
View directory record Official record
Conditions
HIV Infections
Interventions
atazanavir/cobicistat, darunavir/ritonavir dosage #1, darunavir/ritonavir dosage #2, darunavir/ritonavir dosage #3, elvitegravir/cobicistat, dolutegravir, tenofovir alafenamide fumarate (TAF), TAF w/cobicistat, TAF w/cobicistat or ritonavir, efavirenz, darunavir/cobicistat, lopinavir/ritonavir dosage #1, atazanavir/ritonavir/tenofovir dosage #1, rifampicin, ethambutol, isoniazid, pyrazinamide, kanamycin, amikacin, capreomycin, moxifloxacin, levoflaxacin, ofloxacin, ethionamide/prothionamide, terizidone/cycloserine, para-aminosalicylic acid (PAS), high dose INH, bedaquiline, clofazamine, delamanid, linezolid, pretomanid, ethinyl estradiol, etonogestrel implant, nevirapine, amprenavir, abacavir, lopinavir/ritonavir dosage #2, indinavir/ritonavir dosage #1, fosamprenavir/ritonavir, lopinavir/ritonavir dosage #3, atazanavir/ritonavir dosage #1, didanosine delayed release (Videx® EC), emtricitabine, tenofovir, nelfinavir dosage #1, tipranavir/ritonavir, lopinavir/ritonavir dosage #4, raltegravir, etravirine, maraviroc, atazanavir/ritonavir dosage #2, tenofovir/atazanavir/ritonavir dosage #2, nelfinavir dosage #2, indinavir/ritonavir dosage #2, rilpivirine, darunavir/ritonavir dosage #4
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
1,578 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2020
U.S. locations
39
States / cities
Birmingham, Alabama • La Jolla, California • Long Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC

NCT02469246
View directory record Official record
Conditions
HIV-1 Infection
Interventions
F/TAF, ABC/3TC, ABC/3TC Placebo, F/TAF Placebo, 3rd ARV agent
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
34
States / cities
Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2019 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Males to Measure Maraviroc in Blood, Saliva, Seminal Fluid, and Rectal Tissue

NCT00775294
View directory record Official record
Conditions
HIV/AIDS
Interventions
Maraviroc
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 13, 2011 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of Tenofovir, Emtricitabine, Maraviroc, and Raltegravir in Cervical, Vaginal, and Rectal Tissues and Secretions

NCT01330199
View directory record Official record
Conditions
Healthy Adult Females
Interventions
Pharmacokinetic Sampling
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years · Female only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 17, 2013 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

NCT00098293
View directory record Official record
Conditions
HIV-1
Interventions
Maraviroc + Zidovudine/Lamivudine, Efavirenz + Zidovudine/Lamivudine, Maraviroc (UK-427,857) + Zidovudine/Lamivudine
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional Results available

Maraviroc in Patients With Moderate and Severe COVID-19

NCT04435522
View directory record Official record
Conditions
COVID
Interventions
Maraviroc
Drug
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2 Interventional Results available

A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

NCT00827112
View directory record Official record
Conditions
Human Immunodeficiency Virus-1
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Los Angeles, California • Norwalk, Connecticut • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Interaction Study to Assess Drug Levels in Healthy Adult Subjects

NCT00764465
View directory record Official record
Conditions
Healthy
Interventions
Maraviroc, Fosamprenavir, Ritonavir
Drug
Lead sponsor
Garden State Infectious Disease Associates, PA
Other
Eligibility
18 Years to 64 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Maraviroc to Augment Rehabilitation Outcomes After Stroke

NCT03172026
View directory record Official record
Conditions
Stroke
Interventions
Maraviroc 300 mg, Rehabilitation therapy, Placebo 300 mg
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years to 86 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
3
States / cities
Los Angeles, California • New Haven, Connecticut • White Plains, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

NCT00703586
View directory record Official record
Conditions
HIV Infections
Interventions
Maraviroc
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2012 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access Program for Maraviroc At Multiple Centers

NCT00426660
View directory record Official record
Conditions
HIV Infections
Interventions
maraviroc
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
16 Years and older
Enrollment
1,047 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
190
States / cities
Birmingham, Alabama • Hobson City, Alabama • Tucson, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 17, 2026, 3:00 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women

NCT02333045
View directory record Official record
Conditions
HIV
Interventions
Truvada qd, Maraviroc 300 qd
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2Phase 3 Interventional

Maraviroc and NeuroAIDS Pathogenesis

NCT02159027
View directory record Official record
Conditions
AIDS Dementia Complex
Interventions
Maraviroc, Placebo
Drug
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years to 70 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2 Interventional Results available

Therapeutic Intensification Plus Immunomodulation to Decrease the HIV-1 Viral Reservoir

NCT00976404
View directory record Official record
Conditions
HIV Infection
Interventions
DNA + HIV-rAd5 vaccine, ART intensification (raltegravir), ART intensification (maraviroc)
Biological · Drug
Lead sponsor
Robert L. Murphy
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 4 Interventional Results available

Maraviroc as an Immunomodulatory Drug for Antiretroviral-treated HIV Infected Patients Exhibiting Immunologic Failure

NCT00735072
View directory record Official record
Conditions
HIV Infection
Interventions
Placebo, Maraviroc
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
4
States / cities
San Francisco, California • Stanford, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 2 Interventional Results available

Phase II Maraviroc for GVHD Prevention

NCT01785810
View directory record Official record
Conditions
Hematologic Malignancy
Interventions
Maraviroc 300 mg
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 3 Interventional Results available

Switch to Maraviroc + Integrase Inhibitor

NCT01896921
View directory record Official record
Conditions
HIV
Interventions
Switch to Maraviroc + Raltegravir or Dolutegravir
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2021 · Synced Oct 17, 2026, 3:00 AM EDT
Not listed Not applicable Interventional

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

NCT00988780
View directory record Official record
Conditions
Immune Reconstitution Inflammatory Syndrome, HIV, HIV Infections
Interventions
maraviroc, Placebo
Drug
Lead sponsor
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Other
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
4
States / cities
Bethesda, Maryland • Cleveland, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 4 Interventional Results available

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777
View directory record Official record
Conditions
HIV Infections
Interventions
Placebo for maraviroc (MVC), Placebo for dolutegravir (DTG), Dolutegravir (DTG), Maraviroc (MVC)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • Torrance, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2022 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional

Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

NCT01133210
View directory record Official record
Conditions
Hypertriglyceridemia
Interventions
Maraviroc, placebo
Drug · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 10, 2013 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Polymorphic Effects of Cytochrome P450 3A5 on Pharmacokinetics of Maraviroc and Its Metabolites

NCT01980329
View directory record Official record
Conditions
Cytochrome P450 CYP3A5 Enzyme Polymorphism, Healthy Subjects, Pharmacokinetics of Maraviroc
Interventions
Maraviroc
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 17, 2026, 3:00 AM EDT
Completed Not applicable Interventional Results available

Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)

NCT00525733
View directory record Official record
Conditions
HIV Infections
Interventions
darunavir 800 mg, FTC 200 mg/TDF 300mg, Maraviroc, Raltegravir, Ritonavir 100 mg
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2015 · Synced Oct 17, 2026, 3:00 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

NCT06974084
View directory record Official record
Conditions
Long COVID
Interventions
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
Drug
Lead sponsor
HealthBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 17, 2026, 3:00 AM EDT